![]() ![]() The Com-COV programme has now been expanded to include a new study, running across 12 UK National Health Service and academic institutions and backed through funding from the former Vaccine Taskforce (now the COVID Vaccine Unit in the UK Health Security Agency) and the Coalition for Epidemic Preparedness Innovations. This research is the first to report the results of a randomised controlled trial examining the immune response and side effect profiles of standard and mixed vaccine COVID-19 vaccine schedules in adolescents. No vaccine-related safety concerns were raised in this study of 148 participants aged 12 to 16. Although all mixed and non-mixed vaccine schedules used in the study demonstrated favourable side effect profiles, participants who received fractional dose Pfizer-BioNTech as their second vaccine also reported fewer and milder side effects compared to the other study groups. A full dose of Pfizer-BioNTech followed by a fractional (one-third) dose of the same vaccine elicited the lowest antibody concentrations to wild-type COVID-19 but generated similar neutralising antibodies to two-full-doses of Pfizer-BioNTech against both BA.1 and BA.2. ![]() In a paper published in the Journal of Infection, the researchers report that a mixed schedule using a full dose of Pfizer-BioNTech followed by a full dose of Novavax led to fewer break-through infections and generated higher antibody and T cell responses than the licensed two full dose (homologous) Pfizer-BioNTech schedule against both wild-type COVID-19 and Omicron COVID-19 variants, BA.1 and BA.2. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |